Aspire Biopharma (NASDAQ:ASBP – Get Free Report) and OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Insider and Institutional Ownership
19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Aspire Biopharma | N/A | N/A | -398.04% |
| OnKure Therapeutics | N/A | -61.02% | -55.99% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Aspire Biopharma and OnKure Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| OnKure Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
OnKure Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 502.68%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Aspire Biopharma.
Earnings & Valuation
This table compares Aspire Biopharma and OnKure Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspire Biopharma | $10,000.00 | 855.40 | -$24.48 million | ($116.67) | -0.06 |
| OnKure Therapeutics | N/A | N/A | -$59.52 million | ($4.33) | -1.03 |
Aspire Biopharma has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
OnKure Therapeutics beats Aspire Biopharma on 7 of the 12 factors compared between the two stocks.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
